Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7183054 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL8470162 | 1.00 | — | — | |
| SCHEMBL9057827 | 0.99 | — | — | |
| Hydrochloric Acid SCHEMBL8833489 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL8833226 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL7665376 | 0.66 | — | — | |
| SCHEMBL3964704 | 0.64 | — | — | |
| SCHEMBL2634659 | 0.64 | — | — | |
| SCHEMBL1251785 | 0.60 | — | — | |
| Hydrochloric Acid SCHEMBL7665367 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0475413-B1 | Carbocyclic nucleoside analogs useful as immunosuppressants | HOECHST MARION ROUSSEL INC (US) | 1996-06-19 | — | — | EP | claimed |
| US-11858999-B2 | IL-17 receptor A antigen binding proteins | AMGEN K-A, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3165539-B1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN K A INC (US) | 2021-12-08 | — | — | EP | disclosed |
| US-11180564-B2 | IL-17 Receptor A antigen binding proteins | AMGEN K-A, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200362045-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN K-A, INC. | 2020-11-19 | — | — | US | disclosed |
| US-10208122-B2 | IL-17 receptor A antigen binding proteins | AMGEN K-A, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-2492281-B1 | MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF, AND METHOD FOR PREPARING SAME | HANALL BIOPHARMA CO LTD (KR) | 2018-04-11 | — | — | EP | disclosed |
| EP-3165539-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | Kirin-Amgen, Inc. (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-2657252-B1 | MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF AND METHOD FOR PREPARING SAME | HANALL BIOPHARMA CO LTD (KR) | 2017-03-08 | — | — | EP | disclosed |
| EP-2487188-B1 | IL-17 receptor A antigen binding proteins | KIRIN-AMGEN INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20020037524-A1 | IL-17 like molecules and uses thereof | AMGEN INC., A DELAWARE CORPORATION | 2002-03-28 | — | — | US | disclosed |
| US-20020009454-A1 | Composition and method for treating inflammatory diseases | AMGEN INC. | 2002-01-24 | — | — | US | disclosed |
| US-6306820-B1 | FAS ANTIGEN; RHEUMATIC DISEASES, ANTIINFLAMMATORY AGENTS; SEPTIC SHOCK PREVENTION | AMGEN INC. | 2001-10-23 | — | — | US | disclosed |
| US-6294170-B1 | PROTEINACEOUS IL-1 INHIBITOR (INTERLEUKIN-1RA) BY EXTENDED DELIVERY MEANS, E.G., CONTROLLED RELEASE POLYMER FORMULATIONS (HYALURONAN), IL-1RA FUSION PROTEINS AND CHEMICAL ATTACHMENT, AND CONTINUOUS PUMP INFUSION, ARTHRITIS, FUSION PROTEIN | AMGEN INC. | 2001-09-25 | — | — | US | disclosed |
| WO-2001068859-A2 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | AMGEN INC. (US) | 2001-09-20 | — | — | WO | disclosed |
| US-6096728-A | Composition and method for treating inflammatory diseases | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
| US-5605903-A | Carbocyclic nucleoside analogs useful as immunosuppressants | HOECHST MARION ROUSSEL, INC. (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0475413-B1 | Carbocyclic nucleoside analogs useful as immunosuppressants | HOECHST MARION ROUSSEL INC (US) | 1996-06-19 | — | — | EP | disclosed |
| US-5470857-A | Carbocyclic nucleoside analogs useful as immunosuppressants | MARION MERRELL DOW INC. (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0475413-A2 | Carbocyclic nucleoside analogs useful as immunosuppressants | HOECHST MARION ROUSSEL, INC. (US) | 1992-03-18 | — | — | EP | disclosed |